[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"iron-deficiency-anemia-treatment\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:iron-deficiency-anemia-treatment":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,78,108],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100624789","phase-4-the-role-of-ferric-carboxymaltose-in-the-treatment-of-pediatric-iron-deficiency-anemia-in-the-emergency-department-100624789",false,"NCT07414199","The Role of Ferric Carboxymaltose in the Treatment of Pediatric Iron Deficiency Anemia in the Emergency Department","ED-Heme FCM","Inclusion Criteria:\n\n* 1 year to 18 years of age\n* Lab results indicative of anemia due to iron deficiency with Hb between 6.0 g\u002FdL-10.0 g\u002FdL for age and gender\n* Patient is hemodynamically stable\n\nExclusion Criteria:\n\n* Patients \\\u003C1 year or \\> 18 years of age\n* Patients with normal Hb or Hb \\\u003C6 g\u002FdL\n* Overt Bleeding (excluding menstrual bleeding)\n* Traumatic etiology for blood loss\n* Malignancy\n* Thrombocytopenia (platelets \\\u003C100k)\n* Active infection","ALL","1 Year","18 Years",{"count":20,"type":21},150,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The goal of this project is to assess the feasibility, clinical effectiveness, and cost-effectiveness of IV iron therapy using ferric carboxymaltose (FCM) as a treatment for pediatric patients with iron deficiency anemia (IDA) in the emergency department (ED).\n\nThe primary objectives are to:\n\n1. examine and compare healthcare utilization and clinical outcomes of IV FCM use in the pediatric ED compared to historical cohort.\n2. determine the feasibility of IV FCM in the pediatric ED.\n\nA secondary objective of this study is to evaluate if additional laboratory markers such as soluble transferrin receptor (sTfR) or reticulocyte hemoglobin equivalent can serve as potential surrogate markers for diagnosing and monitoring treatment response of IDA between oral iron and IV FCM.\n\nBy evaluating clinical outcomes such as the time to resolution of anemia, hospitalization rates and need for PRBC transfusion, assessing the feasibility of FCM implementation, and secondarily exploring potential adjunct markers for monitoring IDA, this study aims to fill the current research gap and potentially revolutionize management of IDA in pediatric emergency care.",[27,28,29,30,31],"Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease","Iron Deficiency Anaemia Due to Dietary Causes","Iron Deficiency Anemia Treatment","Iron Deficiency Anemia Secondary to IBD or Gastric Bypass","Iron Deficiency Anemias",[33,34,35],"Iron deficiency","anemia","ferric carboxymaltose","NOT_YET_RECRUITING","2026-02-10",{"date":39,"type":40},"2026-02-17","ACTUAL",{"date":42,"type":21},"2026-01-31",{"date":44,"type":21},"2026-12-31",{"name":46,"class":47},"Children's Hospital of Orange County","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":62,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100594048","alternative-vs-once-daily-oral-iron-supplementation-in-iron-deficiency-anemia-ida-100594048","NCT07014371","Alternative vs. Once-Daily Oral Iron Supplementation in Iron Deficiency Anemia (IDA)","Alternative vs. Once-Daily Oral Iron Supplementation in Iron Deficiency Anemia (IDA): A Multicenter, Randomized, Open-Label, Non-Inferiority Trial","Inclusion Criteria:\n\n* Male or female patients aged ≥20 years diagnosed with iron deficiency anemia, defined as: hemoglobin (Hb) \\\u003C13 g\u002FdL in males or \\\u003C12 g\u002FdL in females, and ferritin \\\u003C50 ng\u002FmL or transferrin saturation (TSAT) \\\u003C20%.\n* No iron supplementation within the past 3 months.\n\nExclusion Criteria:\n\n* Hemodynamic instability (e.g., acute bleeding or hypotension).\n* Severe heart failure (New York Heart Association \\[NYHA\\] Class III-IV) or other active cardiac diseases.\n* Active malignancy or history of cancer within the past 3 years (except non-melanoma skin cancer).\n* Pregnancy or breastfeeding.\n* Chronic liver disease including cirrhosis (Child-Pugh class B or C).\n* Chronic kidney disease (estimated glomerular filtration rate \\[eGFR\\] \\\u003C60 mL\u002Fmin\u002F1.73 m²).\n* Clinically significant thalassemia or hemoglobinopathies.\n* Ongoing infection or chronic inflammatory diseases (e.g., rheumatoid arthritis, inflammatory bowel disease).\n* Malabsorption disorders (e.g., history of bariatric surgery).\n* Red blood cell transfusion within the past 3 months.\n\nWithdrawal Criteria\n\n* Withdrawal of informed consent.\n* Severe adverse events requiring permanent discontinuation of study medication.\n* Investigator's judgment that continued participation poses a safety risk.\n* Non-adherence to study medication (compliance \\\u003C 75%).\n\nTreatment Failure\n\n\\- Increase in hemoglobin level of \\\u003C 1 g\u002FdL at Week 4 or Week 8 compared with baseline.","20 Years",{"count":57,"type":21},114,[59],"NA","The goal of this clinical trial is to compare the effectiveness and tolerability of two different oral iron regimens in adults with iron deficiency anemia (IDA). The main questions it aims to answer are:\n\nIs alternate-day oral iron supplementation as effective as once-daily dosing in improving hemoglobin levels?\n\nWhat are the side effects associated with each dosing regimen?\n\nResearchers will compare once-daily vs. alternate-day oral ferrous fumarate to evaluate whether alternate-day dosing is non-inferior in terms of hematologic response, with fewer adverse effects.\n\nParticipants will:\n\nBe randomly assigned to take ferrous fumarate 200 mg once daily or 400 mg on alternate days for 8 weeks\n\nUndergo blood tests and clinical assessments at baseline, Week 4, and Week 8\n\nReport any side effects and bring remaining pills to evaluate medication adherence\n\nThis is a multicenter, randomized, open-label, non-inferiority trial conducted in adults aged 20 years or older with IDA.",[29],[63,64,65,66],"Iron deficiency anemia","Ferrous fumarate","Alternate day dosing","Hemoglobin","RECRUITING","2026-01-05",{"date":70,"type":40},"2026-01-07",{"date":72,"type":40},"2025-06-09",{"date":74,"type":21},"2027-12-31",{"name":76,"class":47},"Phramongkutklao College of Medicine and Hospital",1,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":89,"conditions":90,"keywords":96,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":104,"leadSponsor":106,"locationsCount":77},"100565050","patient-blood-management-in-patients-scheduled-for-cardiac-surgery-100565050","NCT06637137","Patient Blood Management in Patients Scheduled for Cardiac Surgery","Patient Blood Management in Cardiac Surgical Patients: the ICARUS-2 Study","ICARUS-2","Inclusion Criteria:\n\n\\- all adult patients scheduled for elective cardiac surgery\n\nExclusion Criteria:\n\n* pregnancy\n* dyalisis\n* patient's refusal",{"count":87,"type":21},464,"OBSERVATIONAL","The ICARUS 2 study has the general objective of collecting data in patients undergoing cardiac surgery; in our centre, in order to optimize and improve hemoglobin values, a team of haematologists, assisted by cardio anesthetists and cardiac surgeons, will evaluate the blood tests of patients scheduled for elective cardiac surgery in order to correct any states of hypoferritinemia (low iron in the blood) to promote recovery from blood losses related to cardiac surgery. This objective is strongly encouraged by the good use of blood programs currently in force at our foundation.\n\nIn particular, the research presented here intends to demonstrate a reduction in the number of intra- and post-operative transfusions.",[91,92,29,93,94,95],"Anemia","Anemia, Iron-Deficiency","Iron Deficiency Anemia (IDA)","Cardiac Surgical Patients","Blood Loss, Surgical",[97,34,98,99],"iron","cardiac surgery","patient blood management","2025-02-24",{"date":102,"type":40},"2025-02-26",{"date":100,"type":40},{"date":105,"type":21},"2027-02-28",{"name":107,"class":47},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":116,"sex":117,"minAge":18,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":22,"phases":120,"briefSummary":121,"conditions":122,"keywords":125,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":77},"100577460","how-does-perimenopausal-menorrhagia-affect-womens-quality-of-life-and-cognitive-function-100577460","NCT06798584","How Does Perimenopausal Menorrhagia Affect Women's Quality of Life and Cognitive Function?","Rough Journey to Menopause: How Does Perimenopausal Menorrhagia Affect Women's Quality of Life and Cognitive Function?","MENO","Inclusion Criteria:\n\n* Undergoing natural perimenopause\n* English-speaking\n* In general good health as documented by each woman's personal report that the participant is without any past history of a chronic health condition\n\nExclusion Criteria:\n\n* Taking psychoactive drugs\n* A history of hematological disorders",true,"FEMALE",{"count":119,"type":21},240,[59],"The goal of this clinical trial is to investigate how iron status and heavy bleeding during the menopausal transition affect women's cognitive function and quality of life. The main questions it aims to answer are:\n\n* What is the association between iron status, cognitive function, mood, quality of family relationships, and quality of life in perimenopausal women?\n* How does iron repletion, via supplementation, affect cognitive function, mood, quality of family relationships, and quality of life in perimenopausal women?\n\nThe investigators will compare the effect of iron supplements to a placebo (gelatin capsule) to see if iron supplements could improve iron status, cognitive function, mood, quality of family relationships, and quality of life of iron-deficient and\u002For anemic women undergoing the menopausal transition.\n\nEach participant will:\n\n* Make 2 visits (about 2 hours each - baseline and endline) to the Clinical Research Center at Purdue\n* Make a very brief visit at midpoint (about 10 minutes) for a checkup\n* Take a daily study supplement or placebo for 4 months",[29,123,124],"Iron Deficiency","Iron Deficiency (Without Anemia)",[126,127,128,123,129,130,131,132,133,134,135,136,137],"Iron","Perimenopause","Iron Deficiency Anemia","Cognitive Function","Quality of Life","Mood","Quality of Family Relationships","Menopause","Perimenopausal Menorrhagia","Abnormal Uterine Bleeding","Menopause Transition","Women's Health","2025-02-12",{"date":140,"type":40},"2025-02-13",{"date":142,"type":21},"2025-03-01",{"date":144,"type":21},"2025-12",{"name":146,"class":47},"Purdue University"]